Therapeutics News and Research

RSS

Scientists uncover new therapeutic target that could prevent stress-related cell death

Scientists from the Florida campus of The Scripps Research Institute have uncovered a potentially important new therapeutic target that could prevent stress-related cell death, a characteristic of neurodegenerative diseases such as Parkinson's, as well as heart attack and stroke.

3 Jun 2011

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.

3 Jun 2011

Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome

Seaside Therapeutics, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled Phase 3 study to evaluate the effects of STX209 on social impairment in adolescents and adults with fragile X syndrome.

2 Jun 2011

Protox reports net and comprehensive loss of $2.2 million for first quarter 2011

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today announced financial results and achievements for the quarter ended March 31, 2011.

2 Jun 2011

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that one of its clinical trial advisers will present results from an ElectroImmunotherapy clinical trial for melanoma at the 2011 American Society of Clinical Oncology Annual Meeting to be held June 4-8 at McCormick Place, Chicago, IL.

2 Jun 2011

PCF funds 14 new Creativity Awards for advanced prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.

2 Jun 2011

Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia

Somnus Therapeutics, Inc., a private specialty pharmaceutical company, has completed a Phase 2 dose-ranging study of SKP-1041, a modified-release formulation of zaleplon.

2 Jun 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Adaptimmune announced that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy.

1 Jun 2011

CTI regains compliance with all applicable NASDAQ listing standards

Cell Therapeutics, Inc. announced that it has received a letter from The NASDAQ Stock Market LLC, indicating that CTI has regained compliance with the minimum bid price rule (i.e., NASDAQ Listing Rule 5550(a)(2)) for continued listing on The NASDAQ Capital Market and that CTI is in compliance with all applicable listing standards.

1 Jun 2011

Shield raises EUR8.2M through Series A financing

Shield Therapeutics, the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has successfully raised EUR8.2m from Inventages Venture Capital (Inventages) in its first institutional financing round.

1 Jun 2011

Wireless near-infrared spectroscopy can effectively detect bladder disease in children

A cell phone-sized, wireless near-infrared device is as reliable as the current "gold standard" invasive tests in determining bladder disease, according to a study by researchers at the University of British Columbia, Vancouver Coastal Health and the Child & Family Research Institute (CFRI).

1 Jun 2011

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

AVEO Pharmaceuticals, Inc. today announced it has entered into an exclusive license agreement with Centocor Ortho Biotech Inc. for the worldwide development and commercialization of AVEO's internally-discovered antibodies targeting the RON receptor.

1 Jun 2011

FDA approves Oceana's Solesta for treatment of fecal incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.

31 May 2011

Almac's main research projects on ovarian, breast cancer to be presented at ASCO 2011

Two of Almac's main research projects have been selected for presentation at the 2011 ASCO meeting. Both of these studies are based on Almac's approach of profiling large clinical datasets and analysing the data for molecular subgroups that can aid in improved diagnosis of cancer by identifying molecular subtypes and by identifying molecular subgroups which are of clinical and therapeutic relevance.

31 May 2011

Heptares, AstraZeneca partner to discover and develop new GPCR drug targets

AstraZeneca and Heptares Therapeutics today announced they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors.

31 May 2011

Scientists study key malaria protein structure to demonstrate how cells grow and move

Researchers from the Walter and Eliza Hall Institute have overturned conventional wisdom on how cell movement across all species is controlled, solving the structure of a protein that cuts power to the cell 'motor'. The protein could be a potential drug target for future malaria and anti-cancer treatments.

31 May 2011

Therapeutics News and Research

Scientists uncover new therapeutic target that could prevent stress-related cell death

VCU Massey completes Bortezomib-Alvocidib Phase I clinical trial against blood cancers

Seaside Therapeutics commences STX209 Phase 3 study in fragile X syndrome

Protox reports net and comprehensive loss of $2.2 million for first quarter 2011

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

PCF funds 14 new Creativity Awards for advanced prostate cancer research

Somnus Therapeutics completes SKP-1041 Phase 2 trial against sleep maintenance insomnia

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

CTI regains compliance with all applicable NASDAQ listing standards

Shield raises EUR8.2M through Series A financing

Wireless near-infrared spectroscopy can effectively detect bladder disease in children

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

FDA approves Oceana's Solesta for treatment of fecal incontinence

Almac's main research projects on ovarian, breast cancer to be presented at ASCO 2011

Heptares, AstraZeneca partner to discover and develop new GPCR drug targets

Scientists study key malaria protein structure to demonstrate how cells grow and move

Oceana Therapeutics receives FDA approval for Solesta injectable gel to treat fecal incontinence

Tacrolimus prevents breast cancer growth in pre-clinical studies

New genomics research on abnormal brain development

Naturally occurring plant alkaloids could help prevent, delay memory loss linked with Alzheimer's

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News